- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Biocon Limited — Updates, 13-12-2025: Press Release
13-12-2025 | 01:40 pm
13-12-2025 | 01:40 pm
Biocon Biologics secured a global commercialization agreement for its biosimilar Aflibercept (Yesafili®) by settling with Regeneron and Bayer. This expands its ophthalmology market presence, enabling worldwide patient access.
No comments yet. Be the first to comment!